BioTech IP Review

What’s emerging

• AI-designed molecules
• target identification using multi-omics
• in silico screening replacing wet lab steps
• Liquid biopsy and early-detection platforms
• AI-assisted biomarker discovery

Why it’s promising

• Cuts cost and time dramatically
• Big pharma partnerships everywhere
• First AI-designed drugs entering trials
• Clinical demand for early, non-invasive detection
• Strong integration of biology and computation

IP significance

• Tension between:
  • algorithms vs biological outputs
  • patent eligibility
  • inventorship
• Huge opportunity for agents who can bridge software + life science language
• Claims must be grounded in technical implementation, not just correlations
• Medtech + biotech overlap creates unique strategy opportunities